Histogen Inc
NASDAQ:HSTO
Intrinsic Value
Histogen, Inc. engages in the development of potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. [ Read More ]
The intrinsic value of one HSTO stock under the Base Case scenario is 0.11 USD. Compared to the current market price of 0.35 USD, Histogen Inc is Overvalued by 70%.
Valuation Backtest
Histogen Inc
Run backtest to discover the historical profit from buying and selling HSTO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Histogen Inc
Current Assets | 5.5m |
Cash & Short-Term Investments | 4.6m |
Other Current Assets | 890k |
Non-Current Assets | 360k |
Other Non-Current Assets | 360k |
Current Liabilities | 1.4m |
Accounts Payable | 390k |
Accrued Liabilities | 940k |
Other Current Liabilities | 20k |
Non-Current Liabilities | -970k |
Other Non-Current Liabilities | -970k |
Earnings Waterfall
Histogen Inc
Revenue
|
30k
USD
|
Operating Expenses
|
-12.1m
USD
|
Operating Income
|
-12.1m
USD
|
Other Expenses
|
-310k
USD
|
Net Income
|
-12.4m
USD
|
Free Cash Flow Analysis
Histogen Inc
HSTO Profitability Score
Profitability Due Diligence
Histogen Inc's profitability score is 14/100. The higher the profitability score, the more profitable the company is.
Score
Histogen Inc's profitability score is 14/100. The higher the profitability score, the more profitable the company is.
HSTO Solvency Score
Solvency Due Diligence
Histogen Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Histogen Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HSTO Price Targets Summary
Histogen Inc
According to Wall Street analysts, the average 1-year price target for HSTO is 2 USD .
Ownership
HSTO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
HSTO Price
Histogen Inc
Average Annual Return | -68.79% |
Standard Deviation of Annual Returns | 17.73% |
Max Drawdown | -100% |
Market Capitalization | 1.5m USD |
Shares Outstanding | 4 271 760 |
Percentage of Shares Shorted | 1.62% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Histogen, Inc. engages in the development of potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. The company is headquartered in San Diego, California and currently employs 22 full-time employees. The company went IPO on 2013-07-25. The firm is focused on developing its hypoxia-generated growth factor technology platform and stem cell-free biologic products as restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. The firm's product pipelines include CCM Cosmetics, HST 003, HST 004, and Emricasan. In addition, within its small molecule pipeline, its product candidates also include CTS-2090 and CTS-2096. Its HST-003 is a human extracellular matrix (hECM), which is focused on regenerating hyaline cartilage for the treatment of articular cartilage defects in the knee, with a malleable scaffold that stimulates the body’s own stem cells. HST 004 is a cell conditioned medium (CCM) solution, which is used for treatment of spinal disc repair. Emricasan is an orally active pan-caspase inhibitor being developed for the treatment of COVID-19.
Contact
IPO
Employees
Officers
The intrinsic value of one HSTO stock under the Base Case scenario is 0.11 USD.
Compared to the current market price of 0.35 USD, Histogen Inc is Overvalued by 70%.